Earnings summaries and quarterly performance for Pacira BioSciences.
Executive leadership at Pacira BioSciences.
Board of directors at Pacira BioSciences.
Research analysts who have asked questions during Pacira BioSciences earnings calls.
Hardik Parikh
JPMorgan Chase & Co.
5 questions for PCRX
Also covers: RPRX, VKTX
LS
Leszek Sulewski
Truist Securities
3 questions for PCRX
Also covers: AKBA, AMRX, ANIP +6 more
SB
Serge Belanger
Needham & Company
3 questions for PCRX
Also covers: AMPH, ARQT, BCRX +13 more
DT
Douglas Tsao
H.C. Wainwright & Co.
2 questions for PCRX
Also covers: ALKS, APLS, ARGX +21 more
Gary Nachman
Raymond James
2 questions for PCRX
Also covers: ABBV, ACHV, ADMA +9 more
LS
Les Sulewski
Truist
2 questions for PCRX
Also covers: BHC, CRMD, TEVA +1 more
OL
Oren Livnat
H.C. Wainwright
2 questions for PCRX
Also covers: ANIP, AVDL, CARA +7 more
AN
Anish Nikhanj
RBC Capital Markets
1 question for PCRX
Also covers: APTO, CRMD, EXEL +6 more
David Amsellem
Piper Sandler Companies
1 question for PCRX
Also covers: ABBV, ALKS, AMGN +27 more
Denis Reznik
Raymond James
1 question for PCRX
Also covers: AQST, INMB, VERU
DD
Dennis Ding
Jefferies Financial Group Inc.
1 question for PCRX
Also covers: ARDX, CARA, CRNX +9 more
DM
Douglas Miehm
RBC Capital Markets
1 question for PCRX
Also covers: ACB, AUPH, BHC +2 more
Gregory Renza
RBC Capital Markets
1 question for PCRX
Also covers: ACAD, ADCT, AGIO +12 more
JG
John Gionco
Needham & Co.
1 question for PCRX
Also covers: AMPH, CYTK, TRVI
TW
Tejas Wein
Raymond James
1 question for PCRX
Also covers: FOLD
Recent press releases and 8-K filings for PCRX.
Pacira BioSciences Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
PCRX
Earnings
Guidance Update
Share Buyback
- Pacira BioSciences reported Q4 2025 EXPAREL sales of $155.8 million, contributing to full-year 2025 revenue of $726 million and achieving the highest gross margins in company history.
- The company provided 2026 total revenue guidance of $745 million-$770 million, with EXPAREL sales projected at $600 million-$620 million.
- Strategic advancements include expanding EXPAREL coverage to 102 million lives outside the surgical bundle by the end of 2025, with exclusivity secured through 2039.
- In Q4 2025, Pacira executed $50 million in share repurchases, reducing outstanding shares to approximately 41 million, with $150 million remaining on the buyback authorization.
1 day ago
Pacira BioSciences Announces Q4 2025 Results and Strategic Growth Plan
PCRX
Earnings
Guidance Update
New Projects/Investments
- Pacira BioSciences reported $726 million in 2025 revenue and achieved a gross margin of 81%, with its products benefiting over 2.5 million patients.
- The company introduced its "5x30" growth strategy, aiming for double-digit compounded annual product revenue growth and gross margins of at least 81% by 2030, while expanding patient reach to over 3 million annually.
- Key strategic developments include a regional distribution agreement with LG Chem for EXPAREL in Asian-Pacific markets, with revenues anticipated from 2027.
- Commercial coverage for its products significantly expanded in 2025, reaching 102 million covered lives by Q4 2025.
- The pipeline highlights PCRX-201, a gene therapy for Knee OA, which demonstrated unprecedented pain relief and durability in Phase 1 trials and holds RMAT & ATMP designations.
1 day ago
Pacira BioSciences Reports Q4 and Full Year 2025 Results, Issues 2026 Guidance
PCRX
Earnings
Guidance Update
New Projects/Investments
- Pacira BioSciences reported Q4 2025 EXPAREL sales of $155.8 million and full-year 2025 revenue of $726 million, achieving the highest gross margins in its history.
- The company issued 2026 total revenue guidance of $745 million to $770 million, with EXPAREL sales projected at $600 million to $620 million, and non-GAAP gross margins expected between 77% and 79%.
- Strategic achievements include securing EXPAREL exclusivity through 2039, expanding commercial payer coverage to 102 million lives by the end of 2025, and advancing its pipeline with key clinical milestones for PCRX-201, PCRX-2002, and iovera expected in 2026.
- Pacira also returned capital to shareholders, executing $50 million in share repurchases during Q4 2025, reducing outstanding shares to approximately 41 million.
1 day ago
Pacira BioSciences Reports Strong FY 2025 Results and Issues 2026 Guidance
PCRX
Earnings
Guidance Update
Share Buyback
- Pacira BioSciences achieved $726 million in total revenue for full year 2025 and $155.8 million in EXPAREL sales for Q4 2025, with a non-GAAP gross margin of 80% for the quarter.
- The company provided 2026 full-year guidance, projecting total revenue between $745 million and $770 million, with EXPAREL sales expected to be $600 million to $620 million, and non-GAAP gross margins between 77% and 79%.
- Pacira significantly expanded EXPAREL market access, ending 2025 with 102 million lives covered outside the surgical bundle, which increased to 110 million in early 2026, and strengthened EXPAREL's IP runway through 2039.
- The company is advancing its pipeline with PCRX-201 and PCRX-2002, and has established strategic partnerships with LG Chem for ex-U.S. EXPAREL commercialization and J&J MedTech for ZILRETTA in the U.S..
- In Q4 2025, Pacira executed an additional $50 million in share repurchases, reducing outstanding shares to approximately $41 million, with $150 million remaining on its buyback authorization for 2026.
1 day ago
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
PCRX
Earnings
Guidance Update
Share Buyback
- Pacira BioSciences reported full-year 2025 revenues of $726.4 million and GAAP net income of $7.0 million or $0.16 per basic and diluted share. For the fourth quarter of 2025, revenues were $196.9 million and GAAP net income was $1.6 million or $0.04 per basic and diluted share.
- EXPAREL sales reached a record high in 2025, driven by 7 percent volume growth in the fourth quarter. The company also repurchased 5.9 million shares for $150.0 million in full-year 2025, with $150.0 million remaining on its share repurchase authorization as of December 31, 2025.
- For full-year 2026, Pacira provided guidance including total revenue of $745 million to $770 million and EXPAREL net product sales of $600 million to $620 million. Additionally, the company appointed Samit Hirawat, M.D. to its Board of Directors and announced a strategic partnership with LG Chem for EXPAREL in Asian-Pacific markets in January 2026.
1 day ago
Pacira BioSciences Reports Q4 and Full-Year 2025 Financial Results and Issues 2026 Guidance
PCRX
Earnings
Guidance Update
Share Buyback
- Pacira BioSciences reported full-year 2025 revenue of $726.4 million and GAAP net income of $7.0 million, with record-high EXPAREL sales.
- For the fourth quarter of 2025, total revenues increased by 5 percent to $196.9 million, and GAAP net income was $1.6 million.
- The company repurchased 5.9 million shares of common stock for $150.0 million during full-year 2025.
- Pacira issued full-year 2026 financial guidance, forecasting total revenue of $745 million to $770 million and EXPAREL net product sales of $600 million to $620 million.
1 day ago
Pacira Highlights Strong 2025 Performance and Outlines 2026 Growth Catalysts
PCRX
Revenue Acceleration/Inflection
New Projects/Investments
Share Buyback
- Pacira reported unaudited sales of $726 million for the last year (2025) and experienced a 40%+ increase in its stock price between January 2nd and December 28th of that year.
- The company's 5x30 strategy targets double-digit top-line growth and a five-point margin expansion, with a guided margin of 80%-82% from a 76% baseline.
- The Exparel runway is solidified until 2039 due to a volume-limited settlement with Fresenius and Hengrui, supported by 21 patents.
- Strategic initiatives include partnerships with Johnson & Johnson MedTech and LG Chem, and a $150 million stock buyback that reduced outstanding shares to 41 million.
- Pacira expects three significant data readouts in 2026: Zilretta OA shoulder interim results, Iovera Spasticity in the first half, and PCRX201 Phase 2 Part A by year-end.
Jan 14, 2026, 7:15 PM
Pacira Reports Strong 2025 Performance and Outlines 2026 Pipeline Catalysts
PCRX
Revenue Acceleration/Inflection
New Projects/Investments
Share Buyback
- Pacira reported unaudited sales of $726 million for the past year and achieved a 40-plus% increase in its stock price between January 2nd and December 28th. The company is pursuing its 5x30 strategy with goals including double-digit top-line growth and a five-point margin expansion by 2030, guiding to 80%-82% margin.
- The company solidified its Exparel franchise by reaching a volume-limited settlement with Fresenius and Hengrui, providing visibility out to 2039, and strengthening its IP estate to 21 patents. Exparel also saw increased year-over-year volume growth, with Q3 at 9% and Q4 at 7%, driven by expanded commercial coverage reaching 102 million covered lives.
- Key pipeline data catalysts are anticipated in 2026, including interim readout for Zilretta OA of the shoulder, results for Iovera Spasticity in the first half, and PCRX201 Phase 2 Part A data by year-end.
- Pacira executed a $150 million stock buyback and formed significant partnerships with Johnson & Johnson MedTech for Zilretta and LG Chem for Exparel in the Asia-Pacific region.
Jan 14, 2026, 7:15 PM
Pacira Highlights 2025 Achievements and 2026 Growth Drivers at J.P. Morgan Conference
PCRX
Revenue Acceleration/Inflection
New Projects/Investments
Legal Proceedings
- Pacira reported unaudited sales of $726 million for the last year (2025) and experienced a 40+% increase in its stock price between January 2nd and December 28th, 2025.
- The company's 5x30 strategy has led to robust top-line growth and the highest historical margins, supported by a volume-limited settlement for EXPAREL providing visibility until 2039 and a strong IP estate of 21 patents.
- Pacira is entering a data-rich period with key pipeline readouts anticipated in 2026 for ZILRETTA (OA of the shoulder), iovera (Spasticity), and PCRX-201 (Phase II part A).
- Strategic partnerships, including with Johnson & Johnson Medical for ZILRETTA and LG Chem for EXPAREL in Asia-Pacific, are expanding market reach and contributing to growth.
- The NOPAIN legislation has driven market access, with 102 million covered lives by the end of 2025, leading to EXPAREL volume growth of 9% in Q3 2025 and 7% in Q4 2025.
Jan 14, 2026, 7:15 PM
Pacira Biosciences Reports Strong 2025 Revenue and Outlines 5x30 Growth Strategy
PCRX
Guidance Update
Share Buyback
New Projects/Investments
- Pacira Biosciences reported preliminary and unaudited revenue of $726 million for 2025 and projects $726 million in product revenue for 2026. The company also achieved +41% stock price growth from January 2 to December 28.
- The company is advancing its 5x30 growth strategy, aiming for gross margins of 80-82% in 2025 and >= 81% by 2030, supported by $150 million in stock repurchases in 2025 and a TTM Adjusted EBITDA of over $200 million.
- Key initiatives include expanding its clinical pipeline with 5 novel programs and establishing 5 partnerships, such as the EXPAREL regional distribution agreement with LG Chem.
- The NOPAIN Act has significantly expanded commercial coverage in 2025, contributing to 7% year-over-year EXPAREL volume growth in Q4 2025.
Jan 14, 2026, 7:15 PM
Quarterly earnings call transcripts for Pacira BioSciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more